Filicevas Alex, Powles Thomas B
World Bladder Cancer Patient Coalition, Brussels, Belgium.
Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.
Oncol Ther. 2022 Jun;10(1):1-11. doi: 10.1007/s40487-022-00185-5. Epub 2022 Mar 3.
In this plain language podcast, highlights from the European Society for Medical Oncology (ESMO) Congress 2021 are discussed from the perspective of both a patient and a healthcare professional. The patient advocacy track at the congress was co-developed with patients, and was integrated into the overall programme. It included four sessions on the financial impact of cancer, treatments that use the body's immune system to fight cancer, technology, and rare cancers. This comes at a time when there is an increasing focus on the value of real-world data (data from a real-life setting, rather than in a clinical trial) and a more active role for patients and patient organisations as partners in research. Challenges and opportunities arising during the COVID-19 pandemic were also discussed, including logistical complexities in healthcare and consequent uncertainty for patients in accessing care, and opportunities including increased use of telemedicine and broader participation offered by virtual/on-site hybrid congress formats, as used in ESMO 2021. Data discussed on combination treatments for patients with bladder cancer suggest an improved chance of remission for patients intolerant or resistant to existing treatment. Some of the data from studies in kidney cancer also suggest that treatment breaks or longer periods between treatment can improve quality of life and reduce treatment costs, without reducing treatment effectiveness. Although data on bladder and kidney cancer studies were seen to be promising, the authors recognise the time it takes for such findings to reach clinical practice, and the importance of managing expectations in the patient community. The authors conclude their discussion by reflecting on key challenges and opportunities moving forward, including restoring and improving care and efficiency of cancer services, and working together with patient advocates and advocacy organisations as essential partners in achieving this. ESMO Podcast video.
在这个通俗易懂的播客节目中,我们将从患者和医疗保健专业人员的角度讨论2021年欧洲医学肿瘤学会(ESMO)大会的要点。大会上的患者宣传板块是与患者共同开发的,并融入了整体议程。它包括四场会议,分别涉及癌症的经济影响、利用人体免疫系统对抗癌症的治疗方法、技术以及罕见癌症。目前,人们越来越关注真实世界数据(来自现实生活场景而非临床试验的数据)的价值,患者和患者组织作为研究伙伴的作用也更加积极。节目还讨论了新冠疫情期间出现的挑战和机遇,包括医疗保健方面的后勤复杂性以及患者获得护理的不确定性,还有一些机遇,比如远程医疗的使用增加,以及像ESMO 2021采用的虚拟/现场混合会议形式所提供的更广泛参与度。关于膀胱癌患者联合治疗的数据表明,不耐受或对现有治疗有抗性的患者缓解机会有所改善。一些肾癌研究的数据还表明,治疗中断或延长治疗间隔时间可以提高生活质量并降低治疗成本,同时不降低治疗效果。尽管膀胱癌和肾癌研究的数据看起来很有前景,但作者们认识到这些研究结果应用到临床实践所需的时间,以及在患者群体中管理期望的重要性。作者们在讨论结尾反思了未来的关键挑战和机遇,包括恢复和改善癌症服务的护理与效率,以及与患者倡导者和倡导组织合作,将其作为实现这一目标的重要伙伴。ESMO播客视频。